La biotech IA Immunai, fondée en Israël, lance une collaboration de découverte de médicaments avec Boehringer Ingelheim
La collaboration utilisera la plateforme d'IA unicellulaire d'Immunai pour identifier des cibles de lymphocytes T dans les cancers et les maladies auto-immunes.
Évaluation
An Israeli-founded AI biotech firm is partnering with a major pharmaceutical player to apply its single-cell technology to drug discovery. The focus on T-cell targets for both cancer and autoimmune conditions suggests a dual therapeutic ambition. This deal signals deepening industry interest in AI-driven immunology platforms, and the actual targets identified will be the key metric to watch.